A three-judge panel of the CAFC previously decided the appeal, and on September 26, 2011 announced the reversal of the judgment against HemCon that had been entered by the district court in the case.
For the en banc rehearing, the CAFC decided not to request additional briefing or oral argument from the parties. En banc consideration of the appeal will proceed based on the briefs and arguments originally submitted to the court.
"HemCon is confident that the three-judge panel was correct in reversing the judgment of the district court. We expect the en banc Court will confirm that decision," said Nick Hart, HemCon's President and Chief Financial Officer.
HemCon Medical Technologies, Inc. (www.hemcon.com), founded in 2001, develops, manufactures, and markets innovative technologies that control bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental, and clinical settings where rapid control of bleeding is of critical importance. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.
Posted by Sean Fenske, Editor-in-Chief, MDT